Results 31 to 40 of about 2,583,576 (275)

Utilization evaluation of factor concentration and frequencyof bleeds among patients with haemophilia "A" and haemophilia "B" in northwest Iran [PDF]

Journal of Analytical Research in Clinical Medicine, 2013
Background Haemophilia A and B are X-linked bleeding disorders which result in decreased blood levels of coagulants. According to some studies, Hemophilia Severity Score (HSS) is higher in severe Haemophilia A(HA) than in severe Haemophilia B(HB ...
Roya Dolatkhah, Morteza Ghojazadeh, Iraj Asvadi Kermani, Zohreh Sanaat, Nasrin Tavassoli, Mehri Gholchin   +5 more
doaj   +1 more source

Shapes and Positions of Black Hole Shadows in Accretion Disks and Spin Parameters of Black Holes [PDF]

J.Korean Phys.Soc.45:S1808-S1812,2004; Astrophys.J.611:996-1004,2004, 2004
Can we determine a spin parameter of a black hole by observation of a black hole shadow in an accretion disk? In order to answer this question, we make a qualitative analysis and a quantitative analysis of a shape and a position of a black hole shadow casted by a rotating black hole on an optically thick accretion disk and its dependence on an angular ...
arxiv   +1 more source

Spontaneous spinal epidural hematoma in a known case of hemophilia a managed conservatively: A rare case report

Journal of Applied Hematology, 2021
Spontaneous spinal extradural hematomas are rarely attributed to hemophilia. When it occurs, magnetic resonance imaging (MRI) best establishes the diagnosis that should prompt immediate medical or surgical management.
Ashish Acharya, Ravindra Kumar Bind, Sarvpreet Singh Grewal, Paul Sudhakar John   +3 more
doaj   +1 more source

Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A

Haematologica, 2016
Recent evidence suggests that patients with severe hemophilia B may have a less severe disease compared to severe hemophilia A. To investigate clinical, radiological, laboratory and histological differences in the arthropathy of severe hemophilia A and ...
Daniela Melchiorre, Silvia Linari, Mirko Manetti, Eloisa Romano, Francesco Sofi, Marco Matucci-Cerinic, Christian Carulli, Massimo Innocenti, Lidia Ibba-Manneschi, Giancarlo Castaman   +9 more
doaj   +1 more source

Blood clot inspired pore‐gradient nanofiber sponge with “outer filtration” and “inner adsorption” bifunction for rapid stop of uncontrolled hemorrhage

BMEMat, EarlyView.
In this study, by mimicking the nanofiber structure and netting blood cells function of fibrin network in blood clots, we developed a novel bioinspired quaternized chitosan nanofiber sponge with distinct blood cell filtration and blood plasma absorption bifunction for rapid hemostasis.
Fujin Zhou, Yong Yang, Yixuan Li, Ruolin Cao, Zheng Chen, Zhi Wang, Naiwen Tan, Lei Tian, Botao Song   +8 more
wiley   +1 more source

Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study. [PDF]

Am J Hematol
ABSTRACT Despite therapeutic advances, people with hemophilia experience bleeds. These may be life‐threatening, result in permanent joint damage, chronic pain, difficulties with mobility/daily activities, and impact quality of life. In the XTEND‐1 study (NCT04161495), once‐weekly efanesoctocog alfa (50 IU/kg) prophylaxis provided highly effective bleed
Weyand AC, Meunier S, Suzuki N, Bystrická L, Neill G, Abad-Franch L, Willemze A, Tosetto A.   +7 more
europepmc   +2 more sources

A synthetic platform for developing recombinant adeno‐associated virus type 8 producer cell lines

Biotechnology Progress, EarlyView.
Abstract Recombinant adeno‐associated virus (rAAV) is one of the most widely used viral vectors for gene therapy. It is used in very high doses for the treatment of many diseases, making large‐scale production for clinical applications challenging. We have established a synthetic biology‐based platform to construct stable production cell lines, which ...
Yu‐Chieh Lin, Han‐Jung Kuo, Min Lu, Thomas Mahl, George Aslanidi, Wei‐Shou Hu   +5 more
wiley   +1 more source

IQ Survey Results on Current Industry Practices: Part 2—Quantitative Evaluations of Immunogenicity Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
All biotherapeutics have the potential to induce an immunogenic response and generate anti‐drug antibodies (ADAs), especially when administered as multiple doses over prolonged periods. However, a clinically meaningful effect of ADAs can be difficult to identify to communicate the impact of immunogenicity on drug exposure, safety and efficacy outcomes ...
Susan Richards, Insa Winzenborg, Doreen Luedtke, Tao Niu, Lora Hamuro, Karey Kowalski, Jocelyn H. Leu, Jianning Yang, Vaishnavi Ganti, Indranil Bhattacharya, Ivelina Gueorguieva, Nael Mostafa, Christine Grimaldi, Benjamin Wu   +13 more
wiley   +1 more source

The BM@N spectrometer at the NICA accelerator complex [PDF]

arXiv, 2023
BM@N (Baryonic Matter at Nuclotron) is the first experiment operating and taking data at the Nuclotron/NICA ion-accelerating complex.The aim of the BM@N experiment is to study interactions of relativistic heavy-ion beams with fixed targets. We present a technical description of the BM@N spectrometer including all its subsystems.
arxiv  

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source